Siglec-5/Siglec-14 Antibody, anti-human, REAfinity™
Synonyms: CD170, CD33L2, OB-BP2, OBBP2, SIGLEC5, Siglec14
RECOMBINANT
Bioz Star92/100 Bioz rating
3 Citations
Clone:
REA393 | 194128
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for Siglec-5/Siglec-14 Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
APC-Vio 770
Biotin
PE
PE-Vio 770
Vio Bright FITC
Vio Bright V423
Recommended dilution:
1:11
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-106-068, 130-106-019
Description:
Human peripheral blood mononuclear cells (PBMCs) were stained with Anti-Siglec-5/Siglec-14 antibodies or with the corresponding REA Control (S) antibodies (left image), as well as with CD14 antibodies. Flow cytometry was performed with the MACSQuant® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application imageView details view details

Application imageView details view details
MICS (MACSima Imaging Cyclic Staining) applications
APC
PE
Fixation:
frozen – Acetone
Species tested:
human
Recommended dilution:
1:11
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-106-068, 130-106-019
Testing grade:
Specifications for Siglec-5/Siglec-14 Antibody, anti-human, REAfinity™
Overview

Clone REA393 recognizes the human siglec-5 and siglec-14 antigens, which are both single pass transmembrane protein members of the immunoglobulin superfamily. Siglec-5 is also known as CD170. Siglec-5 has four extracellular Ig-like domains and a cytosolic inhibitory motif. Siglec-14 was discovered with three Ig-like domains and has almost complete sequence identity with siglec-5 at the first two Ig-like domains, shows a glycan binding preference similar to that of siglec-5, and associates with the activating adapter protein DAP12. Siglec-5 is expressed on granulocytes and monocytes as well as on plasmacytoid dendritic cells, monocyte-derived dendritic cells, and macrophages. It is potentially involved in the negative regulation of innate immune responses, and also suggested to be a useful diagnostic and therapeutic marker for acute myelogenous leukemia. Siglec-14 is expressed on granulocytes and B cells. Some individuals lack the expression of siglec-14, while they all express siglec-5.

Additional information: Clone REA393 displays negligible binding to Fc receptors.

Alternative names

CD170, CD33L2, OB-BP2, OBBP2, SIGLEC5, Siglec14

Detailed product information

Technical specifications

Clone
REA393
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
Siglec-5/Siglec-14
Molecular mass of antigen [kDa]
51
Distribution of antigen
monocytes, granulocytes, dendritic cells, B cells, macrophages
Entrez Gene ID
RRID
AB_2819695, AB_2922164, AB_2905383, AB_2905384, AB_2653420, AB_2653421, AB_2653419, AB_2928833, AB_2928834, AB_2653414, AB_2653415, AB_2653418, AB_2922130, AB_2819703

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for Siglec-5/Siglec-14 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?